Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24251
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJaninis, J.en
dc.contributor.authorGiannakakis, T.en
dc.contributor.authorAthanasiadis, A.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorNikolaides, K.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorSkarlos, D.en
dc.date.accessioned2015-11-24T19:39:30Z-
dc.date.available2015-11-24T19:39:30Z-
dc.identifier.issn0300-8916-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24251-
dc.rightsDefault Licence-
dc.subjectAntibiotics, Antineoplastic/*adverse effectsen
dc.subjectAntiemetics/*therapeutic useen
dc.subjectBreast Neoplasms/*drug therapyen
dc.subjectDexamethasone/*administration & dosageen
dc.subjectDrug Therapy, Combinationen
dc.subjectEpirubicin/*adverse effectsen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectOndansetron/administration & dosage/*therapeutic useen
dc.subjectSerotonin Antagonists/*therapeutic useen
dc.subjectVomiting/*prevention & controlen
dc.titleA randomized open-label parallel-group study comparing ondansetron with ondansetron plus dexamethasone in patients with metastatic breast cancer receiving high-dose epirubicin. A Hellenic Cooperative Oncology Group studyen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10778764-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2000-
heal.abstractAIMS AND BACKGROUND: The purpose of this multicenter randomized, open-label, parallel-group study was to assess whether the addition of low-dose dexamethasone to ondansetron results in improved control of chemotherapy-induced emesis in patients undergoing first-line chemotherapy with high-dose epirubicin. METHODS & STUDY DESIGN: Patients were randomized to receive either 24 mg of ondansetron or 24 mg of ondansetron plus 8 mg of dexamethasone administered as an intravenous infusion 30 minutes prior to administration of chemotherapy. Both groups of patients received 8 mg of ondansetron given orally from day 2 to 5 two times daily. Fifty-three patients received ondansetron and 50 received ondansetron plus dexamethasone. The patients recorded nausea and the number of vomits and retches daily on diary cards. RESULTS: Significantly more patients in the ondansetron plus dexamethasone group experienced neither vomiting nor retching during the first day of the first course of chemotherapy compared to those receiving ondansetron alone (79.6% vs 53.8%, P = 0.0062). Furthermore, there was a trend in favor of ondansetron plus dexamethasone in the control of nausea. There was no statistically significant difference between ondansetron plus dexamethasone versus ondansetron alone in protecting patients from emesis between days 2 and 5 of the first course of chemotherapy (66.7% vs 62.7%, P = 0.68). This was probably due to the small sample size. Ondansetron was well tolerated, with 15 patients (15%) reporting adverse events such as headache or constipation. CONCLUSIONS: It appears that ondansetron given intravenously in combination with dexamethasone is more effective than ondansetron alone in the control of acute emesis in patients undergoing their first course of chemotherapy with high-dose epirubicin. No difference between the regimens was found with regard to nausea and delayed emesis control.en
heal.journalNameTumorien
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons